<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00429091</url>
  </required_header>
  <id_info>
    <org_study_id>M06-818</org_study_id>
    <nct_id>NCT00429091</nct_id>
  </id_info>
  <brief_title>A Dose-Ranging Study of the Efficacy of ABT-894 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Dose-Ranging Study of the Safety and Efficacy of ABT-894 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott</source>
  <brief_summary>
    <textblock>
      A Dose-Ranging Study of the Efficacy of ABT-894 in Adults with
      Attention-Deficit/Hyperactivity Disorder (ADHD)
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <primary_completion_date type="Actual">August 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CAARS:Inv Total Score (Sum of Inattentive and Hyperactive/Impulsive Sub-scales)</measure>
    <time_frame>Final Evaluation of each 4-week Treatment Period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>CAARS Inattentive and Hyperactive/Impulsive Sub-scales Scores</measure>
    <time_frame>Final Evaluation of each 4-week Treatment Period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CAARS ADHD Index</measure>
    <time_frame>Final Evaluation of each 4-week Treatment Period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CGI-ADHD-S</measure>
    <time_frame>Final Evaluation of each 4-week Treatment Period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AISRS</measure>
    <time_frame>Final Evaluation of each 4-week Treatment Period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CAARS:Self</measure>
    <time_frame>Final Evaluation of each 4-week Treatment Period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TASS</measure>
    <time_frame>Final Evaluation of each 4-week Treatment Period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FTND</measure>
    <time_frame>Final Evaluation of each 4-week Treatment Period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QSU-Brief</measure>
    <time_frame>Final Evaluation of each 4-week Treatment Period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CANTAB cognitive battery</measure>
    <time_frame>Final Evaluation of each 4-week Treatment Period</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">243</enrollment>
  <condition>Attention-Deficit/Hyperactivity Disorder</condition>
  <condition>ADHD</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-894</intervention_name>
    <description>Subjects will take 1 mg QD, 2 mg QD, 4 mg QD, 4 mg BID for up to four weeks.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>atomoxetine</intervention_name>
    <description>Subjects will take 40 mg BID or placebo for up to four weeks.</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Subjects will take BID for up to four weeks</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Meet criteria for attention-deficit/hyperactivity disorder

          -  Have voluntarily signed an informed form

          -  Are between 18 and 60 years of age

          -  Will use contraceptive methods during the study

          -  Women must not be pregnant or breast-feeding

          -  Must be in generally good health

          -  Are fluent in English

        Exclusion Criteria:

          -  They have a current or past diagnosis of schizoaffective disorder, schizophrenia,
             obsessive-compulsive disorder, drug-induced psychosis, bipolar disorder, psychotic
             disorder or mental retardation

          -  They have a current diagnosis of major depressive episode, generalized anxiety
             disorder (GAD), or post-traumatic stress disorder (PTSD) or has a clinically
             significant sleep disorder requiring treatment

          -  They require ongoing treatment or expected treatment with any psychotropic medication,
             including anxiolytics, antipsychotics, anticonvulsants, antidepressants, mood
             stabilizers, nicotine replacement therapies or varenicline

          -  They require ongoing treatment or expected treatment with Coumadin

          -  They failed to respond to two or more adequate trials of FDA-approved ADHD medication

          -  They have taken atomoxetine during the last 3 months

          -  They have violent, homicidal or suicidal ideation

          -  They have a significant history of medical diagnoses, seizure disorder, Tourette's
             syndrome, traumatic brain injury, or a central nervous system (CNS) disease, excluding
             ADHD

          -  They have a urine drug screen that is positive for alcohol or drugs of abuse

          -  They have a history of substance or alcohol disorder during the last 3 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Earle Bain, MD</last_name>
    <role>Study Director</role>
    <affiliation>Abbott</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 5965</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143-0984</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 5955</name>
      <address>
        <city>Wildomar</city>
        <state>California</state>
        <zip>92595</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 5974</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 5956</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 5973</name>
      <address>
        <city>Libertyville</city>
        <state>Illinois</state>
        <zip>60048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 5968</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 5952</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20852</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 5962</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 5954</name>
      <address>
        <city>Okemos</city>
        <state>Michigan</state>
        <zip>48864</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 5970</name>
      <address>
        <city>Troy</city>
        <state>Michigan</state>
        <zip>48085</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 5960</name>
      <address>
        <city>Clementon</city>
        <state>New Jersey</state>
        <zip>08021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 5963</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 5975</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 5971</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19149</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 5957</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 5972</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 5959</name>
      <address>
        <city>Bellaire</city>
        <state>Texas</state>
        <zip>77401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 5969</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 5951</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 5964</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 5953</name>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <zip>23452</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 5958</name>
      <address>
        <city>Bellevue</city>
        <state>Washington</state>
        <zip>98007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 29, 2007</study_first_submitted>
  <study_first_submitted_qc>January 29, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 31, 2007</study_first_posted>
  <last_update_submitted>November 1, 2010</last_update_submitted>
  <last_update_submitted_qc>November 1, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2010</last_update_posted>
  <responsible_party>
    <name_title>Earle Bain, MD</name_title>
    <organization>Abbott</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
    <mesh_term>Hyperkinesis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atomoxetine Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

